Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

A Phase II Study of Brentuximab Vedotin and Bendamustine for Relapsed/Refractory Follicular Lymphoma

Guneet Kaleka, Benjamin Moskoff, Aneeqa Zafar, Naseem S. Esteghamat, Mehrdad Abedi, Francisco Andres Socola, Rasmus T. Hoeg, Joseph M Tuscano

Blood (2024) 144 (Supplement 1): 6318.

https://doi.org/10.1182/blood-2024-210372

Published: 2024

Journal Articles

A Phase I Trial of CC-486, Lenalidomide, Obinutuzumab in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Gabriel Marquez-Arreguin, Tamer Othman, Naseem S. Esteghamat, Mehrdad Abedi, Francisco Andres Socola, Joseph M Tuscano

Blood (2024) 144 (Supplement 1): 6317.

https://doi.org/10.1182/blood-2024-209452

Published: 2024

Journal Articles

Developing and Characterizing the Anti-Tumor Efficacy of a Tri-Specific CAR T Cell Targeting CD19, CD20 and CD22

Michael Sheng, Logan Vick, Craig Collins, Ryan Nielsen, Joseph M Tuscano, Rimas J Orentas, Ying Xiong, William Murphy

Blood (2024) 144 (Supplement 1): 7128.

https://doi.org/10.1182/blood-2024-199366

Published: 2024

Journal Articles

A Phase I Study of CD19 CAR T-Cells with Escalating Doses of Lymphodepletion with or without Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Naseem S. Esteghamat, Joseph M Tuscano, Brian A. Jonas, Aaron S. Rosenberg, Rasmus T. Hoeg, Francisco Andres Socola, Brian Fury, Jordan Pavlic, Geralyn Annett, Jan A. Nolta, Mehrdad Abedi

Blood (2024) 144 (Supplement 1): 2085.

https://doi.org/10.1182/blood-2024-206680

Published: 2024

Journal Articles

Updated Results of a Phase I Study of Uproleselan Combined with Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients with Treatment Naïve Acute Myeloid Leukemia

Brian A. Jonas, Zarir E. Karanjawala, Laura Molnar, Ashley Linh Dang-Chu, Mehrdad Abedi, Naseem S. Esteghamat, Aaron S. Rosenberg, Francisco Andres Socola, Lihong Qi, Joseph M. Tuscano

Blood (2024) 144 (Supplement 1): 1503.

https://doi.org/10.1182/blood-2024-212328

Published: 2024

Journal Articles

Nivolumab-AVD Is Better Tolerated and Improves Progression-Free Survival Compared to Bv-AVD in Older Patients (Aged ≥60 Years) with Advanced Stage Hodgkin Lymphoma Enrolled on SWOG S1826

Blood (2023) 142 (Supplement 1): 181.

https://doi.org/10.1182/blood-2023-180114

Published: 2023

Journal Articles

Intravenous IL-1 Receptor Antagonist for Prevention of Severe Immune Effector Cell-Associated Neurotoxicity Syndrome

Sunmin Park, Christopher Hannigan, Joseph M Tuscano, John Timmerman, Caspian H. Oliai

Blood (2023) 142 (Supplement 1): 4858.

https://doi.org/10.1182/blood-2023-183012

Published: 2023

Journal Articles

Healthcare Resource Utilization in Acute Myeloid Leukemia Treatments: Hypomethylating Agent + Venetoclax Vs. High Intensity Regimens

Margaret Li Krackeler, Benjamin Moskoff, Tamer Othman, Tali Azenkot, Ryan J. Beechinor, Aaron S Rosenberg, Naseem S Esteghamat, Rasmus T Hoeg, Joseph M Tuscano, Brian A. Jonas

Blood (2022) 140 (Supplement 1): 8926–8928.

https://doi.org/10.1182/blood-2022-167966

Published: 2022

Journal Articles

Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL)

Hun Ju Lee, Michael Y. Choi, Tanya Siddiqi, Joanna M. Rhodes, William G. Wierda, Iris Isufi, Joseph M Tuscano, Nicole Lamanna, Suki Subbiah, Jean L. Koff, Lori Leslie, Alec Goldenberg, Gina G Chung, James B. Breitmeyer, Salim Yazji, Michael Wang, Catriona Jamieson, Thomas J. Kipps

Blood (2022) 140 (Supplement 1): 566–568.

https://doi.org/10.1182/blood-2022-167153

Published: 2022

Journal Articles

A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses

Blood (2022) 140 (Supplement 1): 9446–9447.

https://doi.org/10.1182/blood-2022-167173

Published: 2022

Journal Articles

A Phase I Study of Uproleselan Combined with Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients with Treatment Naïve Acute Myeloid Leukemia

Brian A. Jonas, Jeanna L Welborn, Naseem S Esteghamat, Rasmus T Hoeg, Aaron S Rosenberg, Laura Molnar, Ashley Linh Dang-Chu, Susan L Stewart, Joseph M Tuscano

Blood (2022) 140 (Supplement 1): 6213–6214.

https://doi.org/10.1182/blood-2022-168126

Published: 2022

Journal Articles

A Phase II Trial of the Combination of Obinutuzumab, Venetoclax, and Ibrutinib in Patients with Previously Untreated Follicular Lymphoma

Tamer Othman, Aaron S Rosenberg, John Timmerman, Benjamin Heyman, Haifaa Abdulhaq, Joseph M Tuscano

Blood (2022) 140 (Supplement 1): 11954–11955.

https://doi.org/10.1182/blood-2022-164905

Published: 2022

Journal Articles

Identifying Multiple Myeloma Patients Using Automated Data Capture from Electronic Medical Records

Aaron S Rosenberg, Albert William Riedl, Michelle A. Quan, Kwan-Keat Ang, Joseph M Tuscano, Naseem S Esteghamat, Brian A. Jonas, John Graff, Matthew Renquist, Joseph Cawood, Jeanna L Welborn, Rasmus T Hoeg, Paul R. Kaesberg, Kent Anderson, Jason Y Adams, Theresa H.M. Keegan

Blood (2022) 140 (Supplement 1): 7929–7931.

https://doi.org/10.1182/blood-2022-165607

Published: 2022

Journal Articles

Assessing Time to Diagnosis, End-Organ Damage and Treatment Response in Young Newly Diagnosed Multiple Myeloma Patients

Michelle A. Quan, Kwan-Keat Ang, Joseph M Tuscano, Mehrdad Abedi, Brian A. Jonas, Naseem S Esteghamat, Jeanna L Welborn, Paul R. Kaesberg, Aaron S Rosenberg

Blood (2022) 140 (Supplement 1): 7203–7205.

https://doi.org/10.1182/blood-2022-162959

Published: 2022

Journal Articles

An Open-Label Phase II Trial of the Combination of Decitabine, SQ Bortezomib and Pegylated Liposomal Doxorubicin for the Treatment of Patients with Relapsed/Refractory Acute Myelogenous Leukemia

Laura A. Potter, Maria Galkin, Aaron S. Rosenberg, Rasmus T. Hoeg, Mehrdad Abedi, Joseph M. Tuscano, Brian A. Jonas

Blood (2021) 138 (Supplement 1): 2352.

https://doi.org/10.1182/blood-2021-147349

Published: 2021

Journal Articles

First-Line Treatment with R-CHOP Vs Dose-Adjusted R-EPOCH for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis

Tamer Othman, Juan Penaloza, Elizabeth A Brem, Lauren C. Pinter-Brown, Abinav Baweja, Matthew Hyun Joon Lee, Jane Ly, Jack Reid, Haifaa Abdulhaq, Daria Gaut, Caspian Oliai, Erin G. Reid, Joseph M Tuscano

Blood (2021) 138 (Supplement 1): 2509.

https://doi.org/10.1182/blood-2021-151374

Published: 2021

Journal Articles

Interim Results from the First Clinical Study of CC-95251, an Anti-Signal Regulatory Protein-Alpha (SIRPα) Antibody, in Combination with Rituximab in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

Paolo Strati, Eliza Hawkes, Nilanjan Ghosh, Joseph M. Tuscano, Quincy Chu, Mary Ann Anderson, Amar Patel, Michael R. Burgess, Kristen Hege, Sapna Chhagan, Sarandeep Boyanapalli, Tracey Day, Frank Shen, Amitkumar Mehta

Blood (2021) 138 (Supplement 1): 2493.

https://doi.org/10.1182/blood-2021-147292

Published: 2021

Journal Articles

Atezolizumab Combined with Immunogenic Salvage Chemoimmunotherapy (R-GemOx+Atezo) in Patients with Transformed Diffuse Large B-Cell Lymphoma

Alex F. Herrera, Tamer Othman, Paul Frankel, Pamela Allen, Leslie L. Popplewell, Geoffrey Shouse, Tanya Siddiqi, Alexey V. Danilov, Nora Ruel, Shari Daniels, Lacolle Peters, Stella Khoo, Steven T. Rosen, Elad Sharon, Joseph M Tuscano

Blood (2021) 138 (Supplement 1): 1407.

https://doi.org/10.1182/blood-2021-151188

Published: 2021

Journal Articles

A Phase I Study of Anti-ICOS Antibody MEDI-570 for Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Angioimmunoblastic T-Cell Lymphoma (AITL) (NCI-9930)

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-136465

Published: 2020

Journal Articles

Effect of Autologous Hematopoietic Stem Cell Transplant (aHSCT) on the Development of Second Primary Malignancies (SPM) in Multiple Myeloma Patients

Aaron Seth Rosenberg, MD, Ann M Brunson, MS, Joseph M Tuscano, MD, Brian A Jonas, MD PhD, Mehrdad Abedi, MD, Ted Wun, MD FACP, FRCPA, Theresa H.M. Keegan, PhD MS

Blood (2017) 130 (Supplement 1): 332.

https://doi.org/10.1182/blood.V130.Suppl_1.332.332

Published: 2017

NARROW

A Phase II Study of Brentuximab Vedotin and Bendamustine for Relapsed/Refractory Follicular Lymphoma

A Phase I Trial of CC-486, Lenalidomide, Obinutuzumab in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Developing and Characterizing the Anti-Tumor Efficacy of a Tri-Specific CAR T Cell Targeting CD19, CD20 and CD22

A Phase I Study of CD19 CAR T-Cells with Escalating Doses of Lymphodepletion with or without Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Updated Results of a Phase I Study of Uproleselan Combined with Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients with Treatment Naïve Acute Myeloid Leukemia

Nivolumab-AVD Is Better Tolerated and Improves Progression-Free Survival Compared to Bv-AVD in Older Patients (Aged ≥60 Years) with Advanced Stage Hodgkin Lymphoma Enrolled on SWOG S1826

Intravenous IL-1 Receptor Antagonist for Prevention of Severe Immune Effector Cell-Associated Neurotoxicity Syndrome

Healthcare Resource Utilization in Acute Myeloid Leukemia Treatments: Hypomethylating Agent + Venetoclax Vs. High Intensity Regimens

Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL)

A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses

A Phase I Study of Uproleselan Combined with Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients with Treatment Naïve Acute Myeloid Leukemia

A Phase II Trial of the Combination of Obinutuzumab, Venetoclax, and Ibrutinib in Patients with Previously Untreated Follicular Lymphoma

Identifying Multiple Myeloma Patients Using Automated Data Capture from Electronic Medical Records

Assessing Time to Diagnosis, End-Organ Damage and Treatment Response in Young Newly Diagnosed Multiple Myeloma Patients

An Open-Label Phase II Trial of the Combination of Decitabine, SQ Bortezomib and Pegylated Liposomal Doxorubicin for the Treatment of Patients with Relapsed/Refractory Acute Myelogenous Leukemia

First-Line Treatment with R-CHOP Vs Dose-Adjusted R-EPOCH for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis

Interim Results from the First Clinical Study of CC-95251, an Anti-Signal Regulatory Protein-Alpha (SIRPα) Antibody, in Combination with Rituximab in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

Atezolizumab Combined with Immunogenic Salvage Chemoimmunotherapy (R-GemOx+Atezo) in Patients with Transformed Diffuse Large B-Cell Lymphoma

A Phase I Study of Anti-ICOS Antibody MEDI-570 for Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Angioimmunoblastic T-Cell Lymphoma (AITL) (NCI-9930)

Effect of Autologous Hematopoietic Stem Cell Transplant (aHSCT) on the Development of Second Primary Malignancies (SPM) in Multiple Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only